InterCure Ltd. (NASDAQ:INCR) Short Interest Up 72.6% in June

InterCure Ltd. (NASDAQ:INCR) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 47,234 shares, an increase of 72.6% from the May 31st total of 27,374 shares. Based on an average daily volume of 74,696 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company’s shares are sold short.

InterCure Stock Down 4.4%

Shares of NASDAQ:INCR traded down $0.05 on Thursday, reaching $1.08. The company had a trading volume of 33,072 shares, compared to its average volume of 54,574. InterCure has a twelve month low of $0.68 and a twelve month high of $1.77. The stock has a market capitalization of $59.05 million, a P/E ratio of 36.00 and a beta of 1.39. The stock has a 50-day moving average price of $0.93 and a 200 day moving average price of $0.92. The company has a quick ratio of 0.97, a current ratio of 1.48 and a debt-to-equity ratio of 0.20.

InterCure (NASDAQ:INCR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $23.15 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.